AbbVie Inc (ABBV)vsHyperfine Inc (HYPR)
ABBV
AbbVie Inc
$291.27
+1.07%
HEALTHCARE · Cap: $521.11B
HYPR
Hyperfine Inc
$0.72
+4.98%
HEALTHCARE · Cap: $73.43M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 399090% more annual revenue ($66.01B vs $16.54M). ABBV leads profitability with a 15.7% profit margin vs -210.7%. ABBV earns a higher WallStSmart Score of 77/100 (B+).
ABBV
Strong Buy77
out of 100
Grade: B+
HYPR
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-88.0%
Fair Value
$156.84
Current Price
$291.27
$134.43 premium
Intrinsic value data unavailable for HYPR.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 37.2%
Earnings expanding 2282.0% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Revenue surging 44.8% year-over-year
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -101.2% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 37.2%. Revenue growth of 10.3% demonstrates continued momentum.
Bull Case : HYPR
The strongest argument for HYPR centers on Revenue Growth, Price/Book. Revenue growth of 44.8% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.7x leaves little room for execution misses.
Bear Case : HYPR
The primary concerns for HYPR are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a mature stock while HYPR is a hypergrowth play — different risk/reward profiles.
HYPR carries more volatility with a beta of 1.50 — expect wider price swings.
HYPR is growing revenue faster at 44.8% — sustainability is the question.
ABBV generates stronger free cash flow (3.1B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (77/100 vs 30/100), backed by strong 15.7% margins and 10.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Hyperfine Inc
HEALTHCARE · MEDICAL DEVICES · USA
Hyperfine Inc. is a pioneering force in medical technology, renowned for developing the world’s first FDA-cleared portable MRI system, which significantly enhances diagnostic imaging accessibility at the point of care. By combining innovation with cost-efficiency, the company improves patient outcomes and facilitates rapid clinical decision-making. As healthcare continues to evolve, Hyperfine is strategically positioned to capture growth opportunities within the expanding imaging diagnostics market, presenting a compelling investment prospect for institutional investors focused on transformative healthcare solutions.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?